Cravath, Jones Day, Kirkland & Ellis, Ropes & Gray, Slaughter and May and Skadden have grabbed roles on the proposed $32 billion merger between rare disease drug makers Shire plc and Baxalta Inc.
January 11, 2016 at 04:54 PM
1 minute read
The original version of this story was published on The American Lawyer
A half-dozen Global 100 firms have grabbed roles on the proposed $32 billion merger between rare disease drug makers Shire plc and Baxalta Inc.
Dublin-based Shire announced Monday that it had struck a cash-and-stock deal to acquire Bannockburn, Illinois-based Baxalta after a five-month pursuit. Back in August, Shire announced a $30 billion all-stock takeover bid for Baxalta, which was promptly turned down by the target. But Shire sweetened its offer.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Duane Morris LLP seeks a highly motivated junior associate to join its dynamic and growing Labor and Employment Class Action group in Chicag...
Duane Morris LLP seeks a full-time staff litigation attorney who has practiced between 3-5 years. Experience will include drafting motions, ...
Duane Morris LLP has an immediate opening for a senior level, highly motivated litigation associate to join its dynamic and growing Employme...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
